Xzid M 60mg/500mg Tablet ER is a combination oral hypoglycemic agent containing Gliclazide 60mg and Metformin 500mg in an extended-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The extended-release formulation allows for a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Xzid M is typically administered once daily with meals to optimize absorption and minimize hypoglycemia risk. Regular monitoring of blood glucose levels, renal function, and liver enzymes is recommended during therapy. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or elderly patients. This combination therapy offers a synergistic approach to glycemic management, improving patient compliance and therapeutic outcomes in type 2 diabetes mellitus.